

Datasheet: HCA213P

BATCH NUMBER 148233

Description:	HUMAN ANTI INFLIXIMAB:HRP
Specificity:	INFLIXIMAB
Other names:	REMICADE
Format:	HRP
Product Type:	Monoclonal Antibody
Clone:	AbD17841_hIgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			1/100 - 1/1000

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	Total protein concentration 0.1 mg/ml
Immunogen	Infliximab
Specificity	Human Anti-Infliximab, clone AbD17841_hIgG1 is an anti-idiotypic antibody that

specifically recognizes the infliximab monoclonal antibody and inhibits the binding of infliximab to its target. It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

Human anti Infliximab, clone AbD17841_hIgG1 is a fully human antibody and may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera. In the HRP-conjugated format, clone AbD17841_IgG1 is suitable as a detection antibody in pharmacokinetic (PK) assays.

Infliximab (branded as Remicade) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.

Infliximab is directed against Tumor Necrosis Factor Alpha (TNF α) and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNF α expressing T-lymphocytes.

[View a summary of all Anti-Infliximab Antibodies.](#)

Affinity	The monovalent intrinsic affinity of this antibody in an unconjugated format was measured as $K_D=1.8$ nM by real time, label-free molecular interaction analysis on immobilized infliximab.
ELISA	This product may be used in as a detection antibody in an Infliximab bridging ELISA together with HCA212 as the capture reagent. Protocol: PK bridging ELISA to measure free drug
References	1. Hernández-Breijo, B. <i>et al.</i> (2016) Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. Biochem Pharmacol. Sep 21. pii: S0006-2952(16)30302-1. [Epub ahead of print]
Storage	Store at -70°C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Remicade® is a registered trademark of Janssen Biotech Inc. Inflectra® is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS™ is a trademark of Merck Sharp & Dohme Corp.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA213P

Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Useful Reagents

[HUMAN ANTI INFLIXIMAB \(HCA212\)](#)

[RECOMBINANT HUMAN TNF ALPHA \(PHP051\)](#)

[HUMAN ANTI INFLIXIMAB \(HCA214\)](#)

[HUMAN ANTI INFLIXIMAB \(HCA215\)](#)

[HUMAN ANTI INFLIXIMAB \(HCA216\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M371636:200612'

Printed on 03 May 2024